Sangamo Therapeutics (SGMOQ) Cash & Equivalents (2010 - 2025)

Sangamo Therapeutics' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $20.9 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 50.03% year-over-year to $20.9 million in Q4 2025; TTM through Dec 2025 was $20.9 million, a 50.03% decrease from a year earlier, with the FY2025 full-year figure at $20.9 million, down 50.03% from the prior year.
• Cash & Equivalents retreated to $20.9 million in Q4 2025 per SGMOQ's latest filing, from $29.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $178.9 million in Q4 2021 and bottomed at $20.9 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $61.7 million (2023), against an average of $80.3 million.
• Biggest YoY gain for Cash & Equivalents was 43.41% in 2021; the steepest drop was 63.66% in 2021.
• Year by year, Cash & Equivalents stood at $178.9 million in 2021, then slumped by 43.85% to $100.4 million in 2022, then tumbled by 55.0% to $45.2 million in 2023, then declined by 7.27% to $41.9 million in 2024, then plunged by 50.03% to $20.9 million in 2025.
• Per Business Quant, the three latest SGMOQ Cash & Equivalents figures stand at $20.9 million (Q4 2025), $29.6 million (Q3 2025), and $38.3 million (Q2 2025).